These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 30838804)

  • 1. Design, Formulation, and Evaluation of Novel Dissolving Microarray Patches Containing Rilpivirine for Intravaginal Delivery.
    Mc Crudden MTC; Larrañeta E; Clark A; Jarrahian C; Rein-Weston A; Creelman B; Moyo Y; Lachau-Durand S; Niemeijer N; Williams P; McCarthy HO; Zehrung D; Donnelly RF
    Adv Healthc Mater; 2019 May; 8(9):e1801510. PubMed ID: 30838804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, formulation and evaluation of novel dissolving microarray patches containing a long-acting rilpivirine nanosuspension.
    Mc Crudden MTC; Larrañeta E; Clark A; Jarrahian C; Rein-Weston A; Lachau-Durand S; Niemeijer N; Williams P; Haeck C; McCarthy HO; Zehrung D; Donnelly RF
    J Control Release; 2018 Dec; 292():119-129. PubMed ID: 30395897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intradermal delivery of the antiretroviral drugs cabotegravir and rilpivirine by dissolving microarray patches: Investigation of lymphatic uptake.
    Ramöller IK; Volpe-Zanutto F; Vora LK; Abbate MTA; Hutton ARJ; McKenna PE; Peng K; Tekko IA; Sabri A; McAlister E; McCarthy HO; Paredes AJ; Donnelly RF
    J Control Release; 2024 Feb; 366():548-566. PubMed ID: 38211640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and Evaluation of Dissolving Microarray Patches for Co-administered and Repeated Intradermal Delivery of Long-acting Rilpivirine and Cabotegravir Nanosuspensions for Paediatric HIV Antiretroviral Therapy.
    Moffatt K; Tekko IA; Vora L; Volpe-Zanutto F; Hutton ARJ; Mistilis J; Jarrahian C; Akhavein N; Weber AD; McCarthy HO; Donnelly RF
    Pharm Res; 2023 Jul; 40(7):1673-1696. PubMed ID: 36224503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Multiple Dose Phase 1 Assessment of Rilpivirine Long Acting in a Model of Preexposure Prophylaxis Against HIV.
    Cranston RD; Dezzutti CS; Siegel A; Engstrom J; Shetler C; Richardson-Harman N; Abebe KZ; Back D; Else L; Egan D; Khoo S; Egan JE; Stall R; Williams P; Brand RM; Parikh UM; McGowan I
    AIDS Res Hum Retroviruses; 2019 Sep; 35(9):794-804. PubMed ID: 31146534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Acting Rilpivirine (RPV) Preexposure Prophylaxis Does Not Inhibit Vaginal Transmission of RPV-Resistant HIV-1 or Select for High-Frequency Drug Resistance in Humanized Mice.
    Melody K; Roy CN; Kline C; Cottrell ML; Evans D; Shutt K; Pennings PS; Keele BF; Bility M; Kashuba ADM; Ambrose Z
    J Virol; 2020 Mar; 94(8):. PubMed ID: 31969438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rilpivirine long-acting for the prevention and treatment of HIV infection.
    Ferretti F; Boffito M
    Curr Opin HIV AIDS; 2018 Jul; 13(4):300-307. PubMed ID: 29794818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment.
    McGowan I; Dezzutti CS; Siegel A; Engstrom J; Nikiforov A; Duffill K; Shetler C; Richardson-Harman N; Abebe K; Back D; Else L; Egan D; Khoo S; Egan JE; Stall R; Williams PE; Rehman KK; Adler A; Brand RM; Chen B; Achilles S; Cranston RD
    Lancet HIV; 2016 Dec; 3(12):e569-e578. PubMed ID: 27658864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formulation and pharmacology of long-acting rilpivirine.
    Williams PE; Crauwels HM; Basstanie ED
    Curr Opin HIV AIDS; 2015 Jul; 10(4):233-8. PubMed ID: 26049947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, tolerability and pharmacokinetics of rilpivirine following administration of a long-acting formulation in healthy volunteers.
    Verloes R; Deleu S; Niemeijer N; Crauwels H; Meyvisch P; Williams P
    HIV Med; 2015 Sep; 16(8):477-84. PubMed ID: 25988676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low Frequency of Drug-Resistant Variants Selected by Long-Acting Rilpivirine in Macaques Infected with Simian Immunodeficiency Virus Containing HIV-1 Reverse Transcriptase.
    Melody K; McBeth S; Kline C; Kashuba AD; Mellors JW; Ambrose Z
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7762-70. PubMed ID: 26438501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation.
    van 't Klooster G; Hoeben E; Borghys H; Looszova A; Bouche MP; van Velsen F; Baert L
    Antimicrob Agents Chemother; 2010 May; 54(5):2042-50. PubMed ID: 20160045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission.
    Kovarova M; Council OD; Date AA; Long JM; Nochi T; Belshan M; Shibata A; Vincent H; Baker CE; Thayer WO; Kraus G; Lachaud-Durand S; Williams P; Destache CJ; Garcia JV
    PLoS Pathog; 2015 Aug; 11(8):e1005075. PubMed ID: 26271040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of injectable Rilpivirine LA in HPTN 076: A phase 2 HIV pre-exposure prophylaxis study in women.
    Bekker LG; Li S; Pathak S; Tolley EE; Marzinke MA; Justman JE; Mgodi NM; Chirenje M; Swaminathan S; Adeyeye A; Farrior J; Hendrix CW; Piwowar-Manning E; Richardson P; Eshelman SH; Redinger H; Williams P; Sista ND;
    EClinicalMedicine; 2020 Apr; 21():100303. PubMed ID: 32280940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolism of Long-Acting Rilpivirine After Intramuscular Injection: HIV Prevention Trials Network Study 076 (HPTN 076).
    Seneviratne HK; Tillotson J; Lade JM; Bekker LG; Li S; Pathak S; Justman J; Mgodi N; Swaminathan S; Sista N; Farrior J; Richardson P; Hendrix CW; Bumpus NN
    AIDS Res Hum Retroviruses; 2021 Mar; 37(3):173-183. PubMed ID: 33191765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Creation of a long-acting rilpivirine prodrug nanoformulation.
    Hilaire JR; Bade AN; Sillman B; Gautam N; Herskovitz J; Dyavar Shetty BL; Wojtkiewicz MS; Szlachetka A; Lamberty BG; Sravanam S; Fox HS; Alnouti Y; Dash PK; McMillan JM; Edagwa BJ; Gendelman HE
    J Control Release; 2019 Oct; 311-312():201-211. PubMed ID: 31491432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK.
    Rajoli RKR; Flexner C; Chiong J; Owen A; Donnelly RF; Larrañeta E; Siccardi M
    Eur J Pharm Biopharm; 2019 Nov; 144():101-109. PubMed ID: 31525446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults.
    Spreen W; Williams P; Margolis D; Ford SL; Crauwels H; Lou Y; Gould E; Stevens M; Piscitelli S
    J Acquir Immune Defic Syndr; 2014 Dec; 67(5):487-92. PubMed ID: 25473882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rod-shape theranostic nanoparticles facilitate antiretroviral drug biodistribution and activity in human immunodeficiency virus susceptible cells and tissues.
    Kevadiya BD; Ottemann B; Mukadam IZ; Castellanos L; Sikora K; Hilaire JR; Machhi J; Herskovitz J; Soni D; Hasan M; Zhang W; Anandakumar S; Garrison J; McMillan J; Edagwa B; Mosley RL; Vachet RW; Gendelman HE
    Theranostics; 2020; 10(2):630-656. PubMed ID: 31903142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selection of Rilpivirine-Resistant HIV-1 in a Seroconverter From the SSAT 040 Trial Who Received the 300-mg Dose of Long-Acting Rilpivirine (TMC278LA).
    Penrose KJ; Parikh UM; Hamanishi KA; Else L; Back D; Boffito M; Jackson A; Mellors JW
    J Infect Dis; 2016 Mar; 213(6):1013-7. PubMed ID: 26563240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.